Lantheus Holdings Inc. Common Stock (LNTH)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that can earn high returns on capital and are priced with a margin of safety. Lantheus is a specialized radiopharmaceutical company with product lines like DEFINITY and TechneLite, serving heart and cancer diagnostics. That niche can carry regulatory and manufacturing barriers, but the numbers must prove the moat. Financial health is decent: FairStock calculates ROE of 22.21%, debt-to-equity of 0.48, Altman Z-Score of 4.70, and trailing free cash flow of $387.8M, a 5.9% FCF yield. However, ROCE is only 8.38%, so not every dollar of capital is working hard.

In plain English: Lantheus makes medical imaging products used to help diagnose and treat heart and cancer conditions. The business has strong returns, good free cash flow, and low debt, but profits have been slipping recently even as revenue stays roughly flat. At $100.02 on 2026-10-13, the price looks high compared with the company's accounting value and current profits, so it does not look obviously cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer